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Abstract
Background Elevated microsatellite instability at selected tetranucleotide repeats (EMAST) is a genetic signature identified
in 60% of sporadic colon cancers and may be linked with heterogeneous expression of the DNA mismatch repair (MMR)
protein hMSH3. Unlike microsatellite instability-high (MSI-H) in which hypermethylation of hMLH1 occurs followed by
multiple susceptible gene mutations, EMAST may be associated with inflammation and subsequent relaxation of MMR
function with the biological consequences not known. We evaluated the prevalence of EMAST and MSI in a population-
based cohort of rectal cancers, as EMAST has not been previously determined in rectal cancers.
Methods We analyzed 147 sporadic cases of rectal cancer using five tetranucleotide microsatellite markers and National-
Cancer-Institute-recommended MSI (mononucleotide and dinucleotide) markers. EMAST and MSI determinations were
made on analysis of DNA sequences of the polymerase chain reaction products and determined positive if at least two loci
were found to have frame-shifted repeats upon comparison between normal and cancer samples from the same patient. We
correlated EMAST data with race, gender, and tumor stage and examined the samples for lymphocyte infiltration.
Results Among this cohort of patients with rectal cancer (mean age 62.2±10.3 years, 36% female, 24% African American),
3/147 (2%) showed MSI (three males, two African American) and 49/147 (33%) demonstrated EMAST. Rectal tumors from
African Americans were more likely to show EMAST than Caucasians (18/37, 49% vs. 27/104, 26%, p=0.014) and were
associated with advanced stage (18/29, 62% EMAST vs. 18/53, 37%, non-EMAST p=0.02). There was no association
between EMAST and gender. EMAST was more prevalent in rectal tumors that showed peri-tumoral infiltration compared
to those without (30/49, 60% EMAST vs. 24/98, 25% non-EMAST, p=0.0001).
Conclusions EMAST in rectal cancer is common and MSI is rare. EMAST is associated with African-American race and
may be more commonly seen with metastatic disease. The etiology and consequences of EMAST are under investigation,
but its association with immune cell infiltration suggests that inflammation may play a role for its development.
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Microsatellite instability (MSI) is a hallmark of mismatch
repair (MMR) dysfunction and is detected by instability at
mononucleotide or dinucleotide microsatellite DNA
sequences. MSI is seen in patients with Lynch syndrome
and in approximately 15% of patients with sporadic
colorectal cancer. The other 85% of sporadic colorectal
cancers do not demonstrate this MSI pattern and have not
been associated with MMR deficiency.1,2 Alterations
involving specific tetranucleotide microsatellite DNA
sequences, termed “elevated microsatellite alterations at
selected tetranucleotide repeats,” or EMAST, have not been
linked to MMR dysfunction. EMAST has been previously
observed in non-small-cell lung,3,4 skin,5 ovarian,6 and
bladder cancers.5,7 The etiology for EMAST is not known,
but EMAST has been used as a biomarker for some of these
tumors.
Most recently, EMAST has been shown to have a
prevalence of ∼60% among a cohort of sporadic colon
cancers.8 Although the underlying mechanism behind
EMAST remains unknown, the authors suggests that
MSH3, an MMR gene involved in repair of longer repeat
sequences such as those greater than dinucleotide repeats,
may be linked to EMAST due to its “heterogeneous”
immunohistochemical expression in some colon cancers.8
This type of pattern suggests an acquired defect, as no germ
line mutation in MSH3 has ever been demonstrated.2 Some
MMR genes, in particular MSH6 and PMS2, can be
downregulated in the setting of inflammation,9 suggesting
a potential mechanism for “relaxation” of DNA MMR
function. An association between inflammation and
EMAST has not been previously demonstrated.
Rectal cancers have a number of differences from
colon cancers, but both disease processes are often
lumped together in studies as colorectal cancer. Differ-
ences include (a) its embryonic origin, (b) its gender
differences in incidence, (c) its molecular profile of
genes, and (d) its approach to treatment.10–13 Classic
MSI prevalence has been described among cohorts
ranging from 0% to 20%,14–16 but EMAST has never
been evaluated among rectal cancers.
In this study, we evaluated the prevalence of MSI and
EMAST in sporadic rectal cancer. We also analyzed
clinicopathological features including race, gender, and
disease stage and correlated these with EMAST prevalence.
We also correlated the presence of inflammatory cells
histologically with EMAST as a means to assess linkage of
inflammation to EMAST. We observed that sporadic rectal
tumors demonstrate rare MSI but commonly demonstrate
EMAST. In addition, EMAST in rectal tumors is associated
with the African-American race, advanced stage, and the
presence of chronic inflammation.
Methods
Patient Tissue and DNA Extraction
Formalin-fixed, paraffin-embedded tissues from 147 unse-
lected sporadic rectal cancer patients that had linked
epidemiological data were used for this study. Data
included gender, race, age, and tumor stage. Corresponding
normal tissue was microdissected for comparison against
tumor tissue from the same patient. All tissues were
obtained from the North Carolina Rectal Cancer Study
cohort. The project was a population-based cohort assessing
rectal cancer and epidemiological data from 33 counties in
North Carolina.17
Paraffin-embedded normal and tumor tissues were cut
into 5-μm sections, and microdissection was performed
under microscopy. Genomic DNA was isolated using
GeneReleaser (Bioventure, Inc.) and then treated with
proteinase K.18
DNA Amplification
Each matched pair of tumor and normal tissue was
subjected to 35–40 cycles of polymerase chain reaction
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(PCR). PCR was performed in a total volume of 25 μl
inclusive of 10–20 ng of genomic DNA, 0.2 μmol of each
primer, and 20 μl of PCR Supermix (Invitrogen, Inc.). PCR
parameters were as follows for 35–40 cycles: 92°C for
1 min, 58°C for 40 s, and 72°C for 1 min for most primer
sets.
Mononucleotide, Dinucleotide, and Tetranucleotide
Microsatellite Analysis for Rectal Cancer Tissues
Primers for each of the tetranucleotide microsatellite loci
were designed and are listed in Table 1. A total of five
EMAST markers (MYCL1, D20S85, D8S321, D20S82,
and D9S242) and five National Cancer Institute (NCI)-
recommended microsatellite markers (BAT25, BAT26,
D5S346, D2S123, and D17S250)1 were used. All PCR
products were sequenced at the UCSD DNA Sequencing
Facility in order to determine frameshifts (or instability) at
each locus. Classification of microsatellite instability was
performed in accordance with previously established pro-
tocols: tumors were classified as MSI-H if two or more loci
showed instability compared to normal controls, MSI-L if
only one locus demonstrated instability.1 MSS tumors were
classified when no instability occurred at any locus. We
determined EMAST in tumors demonstrating instability at
tetranucleotide loci in at least two or more of the loci
studied when compared to normal controls from the same
patient. Non-EMAST tumors were classified if only one or
no instability in tetranucleotide loci was observed. A locus
was considered unstable if there was a frameshift difference
in the number of repeats between the tumor and normal
samples.
Inflammatory Cell Infiltrate Analysis
Hematoxylin–eosin staining was performed on all 147
samples. Each of the samples was then analyzed by a
single board-certified clinical pathologist to ascertain the
presence of inflammatory cell infiltration within or around
the tumors. The pathologist was blinded to the MSI and
EMAST data.
Statistical Analysis
We performed statistical analysis using the Fisher exact test
between clinicopathologic statuses or degree of inflamma-
tory cell infiltration and the MSS, MSI, and EMAST
groups. All p values represent two-sided statistical tests
with statistical significance at p<0.05.
Results
EMAST Is Common and MSI Is Rare in Rectal Cancers
We utilized 147 rectal cancers that had linked epidemio-
logical data from the North Carolina Rectal Cancer Study.17
We utilized five tetranucleotide markers that have been
traditionally used to define EMAST, and we considered
rectal tumors as EMAST if at least two markers demon-
strated instability. Based on this definition, 49/147 (33%)
demonstrated EMAST. All EMAST tumors were MSS, as
MSI was rare as described below. A representative
sequence demonstrating EMAST loci instability is shown
in Fig. 1 and the frequency of total positive markers is
shown in Table 2. The highest frequency of MSI in
EMAST tumors was demonstrated at the D20S82 locus
(32/49, 65%), followed by the D8S321 locus (30/49, 61%).
The frequency of positive markers for EMAST tumors is
shown in Table 2. The data suggest that EMAST is
common in rectal tumors.
Using the NCI-recommended markers for MSI, only 3/
147 (2%) demonstrated MSI-H. All other tumors were MSS
(Table 3). Thus, in our population-based cohort of rectal
cancer, MSI-H is rare.
EMAST Is Correlated with Patient Race and Tumor Stage
Among the 147 patients in this cohort, the mean age was 62
±10 years (range 43–79). Sixty-two percent of the patients
were male and 26% were African American. Tumor stage
data were available for 82 of the 147 patients in our cohort.
Correlations between age, stage, and gender with MSI and
EMAST and non-EMAST tumors are shown in Tables 3
and 4, respectively. A stage classification of local was
ascribed to stages 1 and 2 while regional classification was
limited to stage 3 and distant to stage 4 rectal cancers.
Rectal tumors in African Americans were more likely to
demonstrate EMAST compared to those in Caucasians
(18/37, 49% vs. 27/104, 26%, p=0.014). EMAST tumors in
Table 1 Tetranucleotide microsatellite PCR primer sequences
Primer Sequence
MYCL1 Fwd: TGG CGA GAC TCC ATC AAA G
Rev: CCT TTT AAG CTG CAA CAA TTT C
D20S85 Fwd: GAG TAT CCA GAG AGC TAT TA
Rev: ATT ACA GTG TGA GAC CCT G
D8S321 Fwd: GAT GAA AGA ATG ATA GAT TAC AG
Rev: ATC TTC TCA TGC CAT ATC TGC
D20S82 Fwd: GCC TTG ATC ACA CCA CTA CA
Rev: GTG GTC ACT AAA GTT TCT GCT
D9S242 Fwd: GTG AGA GTT CCT TCT GGC
Rev: ACT CCA GTA CAA GAC TCT G
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our cohort were associated with a more advanced stage
(stage 3 and above) (18/29, 62% vs. 18/53, 37% advanced
for non-EMAST, p=0.02). There was no gender association
for EMAST tumors (female 20/54, 37% vs. male 29/87,
33%, p=0.717).
EMAST Is Correlated with Chronic Inflammation
We assessed all 147 rectal tumors for the pattern and degree
of chronic inflammation. Invasive margin, intratumoral, and
cancer nests stromal patterns describe inflammatory cells
that surround or are at the peripheral edge of the tumor, are
within the tumor, or surround the epithelial components of
the tumor, respectively. We considered a tumor positive for
inflammation if >50% of an average of five high-power
fields have mononuclear cell infiltrates. With this defini-
tion, 54 tumors were positive for chronic inflammation.
EMAST tumors were associated with chronic inflammation
when compared to non-EMAST tumors (Fig. 2a, Table 4).
Although both EMAST and non-EMAST tumors demon-
strated an invasive margin or leading edge pattern of
inflammation, EMAST tumors showed in addition a
predominant amount of chronic inflammation in the stroma
surrounding tumor nests (Fig. 2ab, Table 5). Neither
EMAST nor non-EMAST tumors demonstrated any intra-
tumoral pattern of inflammatory cell infiltration. The
proximity of inflammatory cells to the epithelia components
of the tumor might influence EMAST formation.
Discussion
This study evaluated the prevalence of MSI and EMAST in
rectal adenocarcinomas and assessed these with available
epidemiological parameters. Rectal cancer, often lumped
together with colon cancer, has unique features from colon
cancer that include its embryologic origin, its gender
differences in incidence, its lower 5-year survivability, its
increased local recurrence, and its treatment algorithms. We
observed that MSI is rare while EMAST is common among
rectal cancers. In this first assessment of clinical parameters
with EMAST, EMAST is associated with African-American
Fig. 1 D8S321 locus instability.
Comparison between the normal
(b) and cancer (b) sequences
from the same patient reveals a
deletion of two tetranucleotide
repeats
Loci MYCL1 D20S85 D8S321 D20S82 D9S242
All rectal tumors
# Times mutated (N=147) 35 (25%) 9 (8%) 43 (30%) 43 (30%) 35 (24%)
EMAST tumors
# Times mutated (N=49) 23 (47%) 5 (10%) 30 (61%) 32 (65%) 24 (49%)
Table 2 Frequency of tetranu-
cleotide marker mutations in
rectal cancers
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race and more advanced disease. Additionally, in the
assessment of chronic inflammation, we found that EMAST
was associated with its presence.
The finding shows that only 2% MSI cases among these
rectal cancers is consistent with other studies.15,16 MSI has
been consistently associated more with right-sided sporadic
colon cancer and less with left-sided tumors.2,20–22
EMAST has not been previously defined in rectal cancers.
Based on our criteria, approximately one third of rectal tumors
demonstrate EMAST. This is about half the prevalence
reported in the two studies of EMAST in colon cancer.8,23 A
potential reason for this discrepancy is our stringent criteria
for at least two tetranucleotide markers positive for its
definition, while other studies indicate that one positive
tetranucleotide marker can define EMAST. Unlike that for
the definition of MSI, there is no consensus on the definition
of EMAST in tumors. To date, there is also no consensus
tetranucleotide marker panel for EMAST, although most
investigators have used similar markers to our study. Yamada
et al. have proposed a panel of 10 tetranucleotide in addition
to the five loci tested in our study, including L17835,
D19S394, L17686, UT5320, and D11S488.23 Because of the
polymorphic nature of tetranucleotide repeats and the ability
of microsatellites to have varying mutation rates based on
their sequence context,24 we used two or more positive
markers to define EMAST. In addition, the majority of the
limited studies on EMAST have used two or more
tetranucleotide loci instability as criteria for determination
of EMAST. To our knowledge, Yamada et al. are the first
authors to use one or more tetranucleotide loci instability as
criteria for the determination of EMAST.
EMAST is a biomarker for several tumors including
endometrial, ovarian, brain, breast, bladder, lung, and soft-
tissue sarcoma.3–7, 25–27 Several studies could find no link
between EMAST and DNA MMR deficiency, the cause of
MSI. While the etiology of EMAST is still not clear,
general clues point toward some epigenetic relaxation of
DNA MMR as one possibility for its cause. It has been
shown that (a) colon cancers have heterogeneous expres-
sion of the DNA MMR protein MSH3,8 suggesting an
acquired loss and (b) oxidative stress has been shown to
reduce the expression of MSH6 and PMS2, causing faulty
DNA MMR that can be corrected when the stress is
removed.9,28 Additionally, we show in the present study a
linkage between EMAST and chronic inflammation, further
suggesting that inflammation may fuel the occurrence of
EMAST in rectal and possibly other tumors. This hypoth-
esis will need to be tested with appropriate experiments to
definitively link EMAST to inflammation. There is a well-
established association between tumorigenesis and inflam-
mation as suggested in numerous studies.29–31 Given this, it
would be of great interest to ascertain if the association with
Table 3 MSI and clinicopathological associations among rectal cancers
MSI-H (N=3) MSS (N=144) p value Total (N=147)
% In cohort population 2% 98% NA 100%
Mean age (SD) 63.7 62.2 NA 62(10)
Gender (M/F) 3/0 (100%/0%) 84/54 (61%/39%) 0.286 87/54 (62%/38%)
Race (black/white) 2/1 (66%/34%) 35/103 (22%/78%) 0.168 37/104 (26%/74%)
Stage
Local (stages 1 and 2) – 46 (56%) NA 46 (56%)
Regional (stages 3 and 4) – 36 (44%) 36 (44%)
Inflammatory cell infiltration (%) – 54(37.5%) NA 54 (37%)
Table 4 EMAST and non-EMAST tumor and clinicopathological associations among rectal cancers
EMAST (N=49) Non-EMAST (N=98) p value Total (N=147)
% In cohort population 33% 67% NA 100%
Mean age (Std dev) 65.2 61.2 NA 62 (10)
Gender (M/F) 29/20 (60%/40%) 58/34 (63%/37%) 0.717 87/54 (62%/38%)
Race (black/white) 18/27 (40%/60%) 19/77 (25%/75%) 0.014 37/104 (26%/74%)
Stage
Local (stages 1 and 2) 11 (38%) 35 (63%) 0.02 46 (56%)
Regional/distant (stages 3 and 4) 18 (62%) 18 (37%) 36 (44%)
Inflammatory cell infiltration (%) 30 (60%) 24 (25%) 0.0001 54 (37%)
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inflammation demonstrated here with EMAST does also
lead to tumorigenesis, either primarily through down-
regulation of specific mismatch repair genes as shown
previously in our lab9 or secondarily via frameshift
mutations of specific genes containing such tetranucleotide
repeats in their sequences. It is our hope that this
preliminary study demonstrating the high prevalence of
EMAST would foster increased research that might help
clarify the biological significance of EMAST.
In our study, EMAST was associated with more
advanced disease compared to non-EMAST tumors. We
also noted a higher incidence of EMAST among rectal
tumors from African Americans compared to Caucasians.
This observation suggests the possibility that EMAST
might be predictive of a reduced survival compared to
non-EMAST tumors, although this has not been evaluated.
In contrast to our results, Yamada et al. did not find any
significant correlation between EMAST and disease
stage.23 One possible reason that could account for the
observed differences between the two studies is the varying
ethnicity in each study (Caucasians and African Americans
vs. Japanese) that makes up our respective cohorts.
In summary, among our rectal cancer cohort, we rarely
found MSI but EMAST has a common prevalence. EMAST
in rectal tumors was associated with tumors from African
Americans and with patients with advanced stage. EMAST
was also associated with the presence of chronic inflam-
matory cells. We suggest that EMAST may confer a poorer
prognosis among rectal cancer patients, and its etiology is
caused by inflammation.
EMAST (N=49) Non-EMAST (98) p value Total
Lymphocyte infiltration 30 (60%) 24 (25%) 0.0001 54
Stromal nests 24 (83%) 4 (17%) <0.0001 28
Margin 30 (100%) 24 (100%) NA 54
Table 5 Lymphocyte infiltra-
tion patterns in EMAST and
non-EMAST rectal tumors
EMAST non-EMAST 
Intratumoral cells  
Immune cells within cancer 
epithelial cell nests  
 




Fig. 2 a Inflammatory cell infiltration in EMAST versus non-EMAST
tumor. A significant increase in inflammatory cell infiltrate is observed
in the stroma of EMAST tumors compared to non-EMAST tumors. b
Pattern of inflammatory cell infiltration. The vast majority of EMAST
tumors demonstrated inflammation within the cancer cell nests and
along the invasive margin. Inflammation in non-EMAST tumors had a
much lower incidence and occurred only along the invasive margin.
Adapted from Naito et al.19
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Discussant
Dr. David Shibata (Tampa, FL): I would like to congratulate
the authors on a very interesting paper and particularly to give
us a greater awareness of what may be a new subset of
mismatch repair deficient colorectal cancer.
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One of my major questions about your study is with
respect to the actual patients that were included in this
study. There are a fair amount of locally advanced rectal
cancers here. So my question is, were any of your tissues
pretreated with chemotherapy and/or radiation?
Closing discussant
Dr. Bikash Devaraj: Most of the stage II and above cancer
patients were treated with preoperative chemo XRT. We did
a subanalysis trying to determine just that, and we found
that there was no relation between advanced stage and
inflammation at this point.
Discussant
Dr. David Shibata (Tampa, FL): I think it's interesting,
and this brings up an important point, that MSH3 is a very
quirky mismatch repair gene and, in fact, it's very
heterogenous in terms of its expression, even between
individual tumor cells. In fact, it may be—as you stated—
that the expression is impacted by cellular stress. So I
would be very curious to see, and I think it would be
interesting for your study, to do MSH-3 immunohistochem-
istry on your specimens, and particularly for those patients
that were treated with radiation. It would be very interesting
to see what the correlation would be between EMAST and
MSH3 in those tissues.
The other question then is, given that this seems to be a
state-based registry, why is there such a lack of data on
tumor stage on almost half of the patients?
Closing discussant
Dr. Bikash Devaraj: I don't have a good answer to that
question at this point.
Discussant
Dr. David Shibata (Tampa, FL): Because I think in terms of
making a statement on prognosis and stage, to have half of
your patients not having stage data, I think if you can try to
get that, I think that would strengthen things, certainly.
Closing discussant
Dr. Bikash Devaraj: But, again, if you look at the overall
correlation and as you know, about half of them are not
there, them we did not have stage data for—it's about
equivalent in terms of the stage that we have for EMAST
tumors versus non-EMAST tumors. Thus, so I still think
you can draw a correlation between the two.
Discussant
Dr. David Shibata (Tampa, FL): And finally, I think the
other studies that you had cited invariably show that MSI-
high tumors were all EMAST positive. And I'm just
wondering whether you did genetic testing on these
patients. Were they HNPCC perhaps and not just sporadic
MLH1 deficient tumors?
Closing discussant
Dr. Bisash Devaraj: As far as we know, none of these
patients were HNPCC patients. And you are correct, the
majority of the papers out there do show that EMAST
tumors tend to be MSI-high tumors, too. But again, we had
such low numbers of traditional MSI-high tumors that this
may be one of the reasons why we did not see that
correlation.
Discussant
Dr. David Shibata (Tampa, FL): Did you categorize any
as MSI-low?
Closing discussant
Dr. Bikash Devaraj: No, we did not.
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